



New York Life Global Funding
\$45,000,000,000
(increased from \$40,000,000,000)
GLOBAL DEBT ISSUANCE PROGRAM

This supplement (“Third Offering Memorandum Supplement”) is supplemental to and must be read in conjunction with the Offering Memorandum, dated March 26, 2025, as supplemented by the First Offering Memorandum Supplement, dated May 23, 2025 and the Second Offering Memorandum Supplement, dated August 20, 2025 (the “Offering Memorandum”), prepared by New York Life Global Funding (the “Issuer”) under the Issuer’s \$45,000,000,000 (increased from \$40,000,000,000) Global Debt Issuance Program (the “Program”) for the issuance of senior secured medium-term notes (the “Notes”).

This Third Offering Memorandum Supplement constitutes a “Base Listing Particulars Supplement” for the purposes of listing on the Official List and trading on the Global Exchange Market. The Irish Stock Exchange Plc, now trading as Euronext Dublin, has approved this Third Offering Memorandum Supplement. References herein to this document are to this Third Offering Memorandum Supplement incorporating Annex 1 hereto.

On November 19, 2025, New York Life Insurance Company (“New York Life”) published its interim condensed unaudited financial statements as of September 30, 2025 (including any notes thereto, the “Third Quarter 2025 Financial Statements”) and on November 19, 2025 made available New York Life’s Summary of Certain Third Quarter Financial Information, Certain Financial and Accounting Matters, Statutory Capitalization of New York Life, and Selected Historical Statutory Financial Information of New York Life (collectively, the “Third Quarter 2025 Financial Information”). Annex 1 to this document sets out the Third Quarter 2025 Financial Information at pages 3 to 24 and the Third Quarter 2025 Financial Statements at pages 25 to 39. Copies of the Third Quarter 2025 Financial Information and the Third Quarter 2025 Financial Statements will be made available for inspection at the offices of the parties at whose offices documents are to be available for inspection as identified in “General Information” in the Offering Memorandum.

With effect from the date hereof, the maximum aggregate principal amount of Notes that may be outstanding at any one time under the Program (the “Program Size”) is increased from the current limit of \$40,000,000,000 to \$45,000,000,000 (or the equivalent in foreign or composite currencies), and all references to the Program Size of \$40,000,000,000 in the Offering Memorandum, including the Form of Pricing Supplement contained therein, shall be read and construed as \$45,000,000,000.

Except as disclosed in this document, there has been no other significant new factor, material mistake or inaccuracy relating to the information included in the Offering Memorandum, nor has there been any significant change in the financial or trading position of New York Life since September 30, 2025 (the date of the Third Quarter 2025 Financial Statements).

Each of the Issuer and New York Life accepts responsibility for the information contained in this Third Offering Memorandum Supplement. To the best of the knowledge of each of the Issuer and New York Life (having taken all reasonable care to ensure that such is the case) the information contained in this Third Offering Memorandum Supplement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Where there is any inconsistency among the Offering Memorandum and this Third Offering Memorandum Supplement, the language used in this Third Offering Memorandum Supplement shall prevail.

Third Offering Memorandum Supplement dated November 19, 2025

ANNEX 1

SUMMARY OF CERTAIN THIRD QUARTER FINANCIAL INFORMATION

Results of Operations – For the Nine Months Ended September 30, 2025 Compared to the Nine Months Ended September 30, 2024

Net Income/(Loss)

New York Life's net loss, which is comprised of net gain/(loss) from operations after dividends to policyholders and federal and foreign income taxes plus net realized capital gains (losses) (after-tax and transfers to the interest maintenance reserve ("IMR")), was \$118 million for the nine months ended September 30, 2025, representing a decrease of \$822 million compared to New York Life's net income of \$704 million reported for the nine months ended September 30, 2024. The decrease in net income year-over-year was primarily driven by a \$588 million decline in net gain from operations after dividends and taxes, and a \$233 million increase in realized capital losses.

Net Gain from Operations

As a mutual insurance company, all dividends paid by New York Life to participating policyholders are included in net gain from operations. However, since dividends are supported by unassigned surplus, not all of the sources that support dividends are reported in pre-dividend net gain (such as capital gains (losses) and undistributed earnings from subsidiaries). Therefore, focusing on net gain from operations before dividends to policyholders and federal and foreign income taxes provides the best insight into New York Life's performance.

Net gain from operations before dividends to policyholders and federal and foreign income taxes for the nine months ended September 30, 2025 was \$2,182 million, representing a decrease of \$526 million, or 19%, when compared to the net gain from operations before dividends to policyholders and federal and foreign income taxes of \$2,708 million reported for the nine months ended September 30, 2024. While results reflect higher bond income, driven by both higher yields and increased average invested assets, and lower operating expenses, the year-over-year decrease was primarily driven by lower U.S. insurance subsidiary dividends (see "—Net Investment Income (including amortization of IMR)" and "—Operating Expenses").

Dividends to policyholders and federal and foreign income tax expense/(benefit) for the nine months ended September 30, 2025 were \$2,045 million and \$(118) million, respectively, and for the nine months ended September 30, 2024 were \$1,844 million and \$20 million, respectively (see "—Dividends to Policyholders" and "—Federal and Foreign Income Taxes").

Net gain from operations after dividends to policyholders and federal and foreign income taxes was \$255 million and \$844 million for the nine months ended September 30, 2025 and 2024, respectively.

Premium Income

Premium income is primarily generated from sales of life insurance, annuities, long-term care ("LTC") insurance and disability insurance. In addition, sales of Institutional Annuities, with annuity purchase rate guarantees, are considered premium income since there is mortality risk in these products.

Premium income from the insurance business primarily consists of recurring premiums from New York Life's agency sold life insurance business, while premium income from the annuities business is generally single premium and can be more volatile from year to year.

The following table shows premium income by business operation for the nine months ended September 30, 2025 and 2024 (\$ in millions):

	2025	2024	Change	
			\$	%
Life Insurance Solutions	\$ 7,192	\$ 7,035	\$ 157	2 %
New York Life Direct	1,226	1,202	24	2
Group Membership	468	476	(8)	(2)
LTC	295	287	8	3
Closed Block Reinsurance	83	82	1	1
Individual Disability Insurance	3	2	1	50
Total Insurance Business ¹	<u>9,267</u>	<u>9,084</u>	<u>183</u>	<u>2</u>
Institutional Annuities	3,916	3,024	892	29
Retail Annuities	638	743	(105)	(14)
Total Annuities Business	<u>4,554</u>	<u>3,767</u>	<u>787</u>	<u>21</u>
Total	<u>\$ 13,821</u>	<u>\$ 12,851</u>	<u>\$ 970</u>	<u>8 %</u>

¹ Recurring premiums account for 82% of the total insurance business for the nine months ended September 30, 2025 and 2024, respectively.

Life Insurance Solutions premiums for the nine months ended September 30, 2025 increased \$157 million compared to the nine months ended September 30, 2024, primarily due to higher paid up additions on whole life products.

Institutional Annuities premiums for the nine months ended September 30, 2025 increased \$892 million compared to the nine months ended September 30, 2024, primarily due to higher sales of stable value products.

Retail Annuities premiums for the nine months ended September 30, 2025 decreased \$105 million compared to the nine months ended September 30, 2024, primarily due to lower sales of participating income annuities.

Net Investment Income (including amortization of IMR)

The following table shows investment income based on components of New York Life’s investment portfolio for the nine months ended September 30, 2025 and 2024 (\$ in millions):

	2025	2024	Change	
			\$	%
Bonds.....	\$ 5,131	\$ 4,700	\$ 431	9 %
U.S. Insurance Subsidiary Dividends ¹	—	890	(890)	(100)
Mortgage Loans.....	913	748	165	22
Policy Loans	590	564	26	5
Other Invested Assets ²	522	383	139	36
Real Estate	318	325	(7)	(2)
Equity Securities.....	24	21	3	14
Other	220	230	(10)	(4)
Gross Investment Income	7,718	7,861	(143)	(2)
Investment Expenses ³	(725)	(743)	18	2
Net Investment Income	6,993	7,118	(125)	(2)
Amortization of IMR	12	17	(5)	(29)
Total	\$ 7,005	\$ 7,135	\$ (130)	(2)%

1 Dividends from the wholly owned U.S. insurance subsidiaries of New York Life. The timing of dividends from New York Life’s subsidiaries may vary from year to year and the amount of dividends received can vary subject to the capital needs of the subsidiaries as well as regulatory requirements for the payment of dividends by New York Life’s insurance company subsidiaries.

2 Includes \$157 million of dividends from non-insurance subsidiaries of New York Life as of September 30, 2025.

3 Investment expenses include interest expense on surplus notes.

Net investment income for nine months ended September 30, 2025 decreased \$130 million compared to the nine months ended September 30, 2024, primarily due to lower U.S. insurance subsidiary dividends. This was partially offset by higher bond income, driven by increased average invested assets, improved yields and higher limited partnership (“LP”) distribution from dividend income received from wholly owned subsidiaries of New York Life.

Other Income

The following table shows the primary components of other income for the nine months ended September 30, 2025 and 2024 (\$ in millions):

	2025	2024	Change	
			\$	%
Investment in COLI policies	\$ 199	\$ 215	\$ (16)	(7)%
Commission and expense allowance on reinsurance ceded	96	65	31	48
Net loss on derivatives hedging funding agreements	(146)	(151)	5	3
Other	48	41	7	17
Total	\$ 197	\$ 170	\$ 27	16 %

New York Life has purchased various corporate-owned life insurance (“COLI”) policies from New York Life Insurance and Annuity Corporation (“NYLIAC”) for the purpose of informally funding non-qualified pension and post-retirement plans and deferred compensation plans. NYLIAC holds the underlying assets supporting these policies. Income from these policies represents the net change in cash surrender value, driven by the performance of the underlying assets supporting the policies. The income from the investment in COLI policies during the nine months ended September 30, 2025 was lower compared to the nine months ended September 30, 2024, largely due to lower equity returns in 2025. This was primarily passed on to participants in certain deferred compensation plans, and therefore was partially offset by lower interest credited expense included in general operating expenses (see “—Operating Expenses”).

Commission and expense allowance on reinsurance ceded for the nine months ended September 30, 2025 increased \$31 million compared to the nine months ended September 30, 2024, primarily due to amortization of the deferred gain from surplus in 2025 related to the Term Reinsurance Agreement and ongoing policy administration charges (see “Certain Financial and Accounting Matters—Reinsurance”).

Other income also includes the net loss on settlement of derivatives that hedge either foreign exchange exposure on foreign denominated funding agreements or manage interest rate risk on funding agreements issued under the Program. Although these derivatives generated losses, their financial impact was largely offset by either lower benefit payments in Institutional Annuities due to foreign exchange on benefit payments or higher net investment income earned on floating rate assets as interest rates rose (see “—Net Investment Income (including amortization of IMR)” and “—Benefit Payments”).

Benefit Payments

New York Life’s benefit payments primarily include death benefits, annuity benefits, LTC benefits, disability benefits, surrender benefits (including scheduled maturities and withdrawals on Institutional Annuities) and interest on policy claims and deposit funds.

The following table shows benefit payments by business operation for the nine months ended September 30, 2025 and 2024 (\$ in millions):

	2025	2024	Change	
			\$	%
Life Insurance Solutions	\$ 4,275	\$ 4,117	\$ 158	4 %
New York Life Direct	800	775	25	3
Group Membership	270	297	(27)	(9)
LTC	151	136	15	11
Closed Block Reinsurance	303	304	(1)	—
Total Insurance Business	5,799	5,629	170	3
Institutional Annuities	7,151	5,783	1,368	24
Retail Annuities	122	106	16	15
Total Annuities Business	7,273	5,889	1,384	24
Total	\$ 13,072	\$ 11,518	\$ 1,554	13 %

Life Insurance Solutions benefit payments for the nine months ended September 30, 2025 increased \$158 million compared to the nine months ended September 30, 2024, primarily driven by higher surrenders on whole life products as lapse rates normalize to pre-pandemic levels.

Institutional Annuities benefit payments for the nine months ended September 30, 2025 increased \$1,368 million compared to the nine months ended September 30, 2024, primarily driven by higher withdrawals related to the rebalancing of New York Life’s Defined Benefit Pension Plans (“**Pension Plans**”) (see “—Net Transfers to (from)

Separate Accounts”), as well as scheduled maturities for guaranteed investment contracts (“GICs”) and funding agreements.

Net Additions to Reserves

The following table shows net additions to reserves by business operation for the nine months ended September 30, 2025 and 2024 (\$ in millions):

	2025	2024	Change	
			\$	%
Life Insurance Solutions	\$ 3,506	\$ 3,384	\$ 122	4 %
New York Life Direct	88	91	(3)	(3)
Group Membership	(1)	(19)	18	95
LTC	235	212	23	11
Closed Block Reinsurance	(163)	(153)	(10)	(7)
Individual Disability Insurance	1	2	(1)	(50)
Total Insurance Business	3,666	3,517	149	4
Institutional Annuities	(51)	159	(210)	(132)
Retail Annuities	508	578	(70)	(12)
Total Annuities Business	457	737	(280)	(38)
Total	\$ 4,123	\$ 4,254	\$ (131)	(3)%

Life Insurance Solutions additions to reserves for the nine months ended September 30, 2025 increased \$122 million compared to the nine months ended September 30, 2024, primarily due to higher paid up additions on whole life products.

Institutional Annuities additions to reserves for the nine months ended September 30, 2025 decreased \$210 million compared to the nine months ended September 30, 2024, primarily driven by lower net flows on GICs, partially offset by higher net flows into stable value products.

Retail Annuities additions to reserves for the nine months ended September 30, 2025 decreased \$70 million compared to the nine months ended September 30, 2024, primarily due to lower sales of participating income annuities.

Net Transfers to (from) Separate Accounts

New York Life’s transfers to separate accounts reflect policyholder premium payments. New York Life’s transfers from separate accounts reflect benefit payments or fund transfers between the separate accounts and the general account during the reporting period (see “Certain Financial and Accounting Matters—Separate Accounts”).

The following table shows the components of the net transfers to (from) separate accounts for the nine months ended September 30, 2025 and 2024 (\$ in millions):

	2025	2024	Change	
			\$	%
Transfers to separate accounts	\$ 1,770	\$ 1,334	\$ 436	33 %
Transfers from separate accounts	(2,828)	(2,477)	(351)	(14)
Total	\$ (1,058)	\$ (1,143)	\$ 85	7 %

Transfers to separate accounts for the nine months ended September 30, 2025 increased \$436 million compared to the nine months ended September 30, 2024, primarily related to higher premiums into separate account stable value products. Transfers from separate accounts for the nine months ended September 30, 2025 increased \$351 million compared to the nine months ended September 30, 2024, primarily due to higher transfers to the general account due to rebalancing within the Pension Plans separate account contracts, partially offset by lower withdrawals from separate account stable value products (see “—Premium Income” and “—Net Additions to Reserves”).

Adjustments in Funds Withheld

New York Life at times enters into reinsurance agreements to coinsure its liabilities with other insurers, under which New York Life may retain the assets supporting the reinsured liabilities and establish a corresponding funds withheld liability. The adjustments in funds withheld generally represents the establishment of the funds withheld liability and related interest. Adjustments in funds withheld was \$103 million and \$107 million for the nine months ended September 30, 2025 and 2024, respectively, which was related to interest credited on reinsurance agreements (see “Certain Financial and Accounting Matters—Reinsurance”).

Operating Expenses

The following table shows the components of operating expenses for the nine months ended September 30, 2025 and 2024 (\$ in millions):

	2025	2024	Change	
			\$	%
General operating expenses ¹	\$ 2,084	\$ 2,171	\$ (87)	(4)%
Variable sales expenses ²	517	541	(24)	(4)
Total	\$ 2,601	\$ 2,712	\$ (111)	(4)%

1 General operating expenses include, but are not limited to, salaries, incentive compensation, licenses and fees, charitable contributions and rent expense.

2 Variable sales expenses include agents’ commissions and premium tax expense.

General operating expenses for the nine months ended September 30, 2025 decreased \$87 million compared to the nine months ended September 30, 2024, primarily driven by lower post-retirement benefits expenses due to an increase in assumed discount rates for New York Life’s pension and other post-retirement benefits plans and a post-retirement health plan amendment. Additionally, the decrease in general operating expenses was driven by lower interest crediting expense on deferred compensation plans due to lower equity returns, which was partially offset by a decrease in income on investment in COLI policies (see “—Other Income”).

Dividends to Policyholders

The following table shows dividends to policyholders for the nine months ended September 30, 2025 and 2024 (\$ in millions):

	2025	2024	Change	
			\$	%
Dividends - New York Life policyholders	\$ 2,006	\$ 1,808	\$ 198	11 %
Dividends - Closed Block Reinsurance ¹	39	36	3	8
Total	\$ 2,045	\$ 1,844	\$ 201	11 %

¹ Dividends for the Closed Block Reinsurance are approved by the ceding company.

Dividends to New York Life policyholders are approved by New York Life’s board of directors (the “**Board of Directors**”) annually and primarily factor in investment experience (interest earnings, credit loss experience and equity returns), mortality results and expense levels that develop over a period of time (see “Certain Financial and Accounting Matters—Dividends to Policyholders”).

Federal and Foreign Income Taxes

In accordance with Statutory Accounting Principles (“**SAP**”), prescribed or permitted by the New York State Department of Financial Services (the “**NYDFS**”), current federal and foreign income taxes are reflected in net income, whereas deferred tax items are reflected as a component of surplus. Therefore, differences between the statutory tax rate and book income to tax expense includes temporary book/tax differences in addition to permanent differences. The following table reconciles the tax expense calculated at the statutory rate to the tax benefit reflected in New York Life’s results of operations for the nine months ended September 30, 2025 and 2024 (in millions):

	<u>2025</u>	<u>2024</u>	<u>Change</u>
Tax expense on net gain from operations	\$ 29	\$ 181	\$ (152)
Dividends from subsidiaries ¹	(35)	(189)	154
Compensation and benefits accrual	(11)	—	(11)
Tax credits ²	(74)	(66)	(8)
Tax exempt income	(68)	(71)	3
Excess of book over tax reserves	81	75	6
Deferred acquisition costs tax	37	29	8
Non-deductible pension and post-retirement benefits	6	19	(13)
Prior year return to provision adjustments	(32)	(11)	(21)
Other ³	(51)	53	(104)
Total federal and foreign income tax expense/(benefit)	\$ (118)	\$ 20	\$ (138)

1 Dividends from subsidiaries represent after-tax earnings of the subsidiaries and are not subject to tax when received by New York Life.

2 Tax credits result primarily from investments in low-income housing and alternative energy.

3 Other consists mostly of changes in accruals and partnerships.

The One Big Beautiful Bill Act was enacted on July 4, 2025. New York Life has evaluated the impacts of the Act and there was no material impact on its surplus position as a result of the Act.

Net Realized Capital Losses

New York Life reported net realized capital (losses) after taxes and transfers to the IMR of \$(373) million for the nine months ended September 30, 2025, an increase of \$233 million from the net realized capital losses of \$(140) million reported for the nine months ended September 30, 2024.

The following table represents net realized capital gains (losses) for the nine months ended September 30, 2025 and 2024 (in millions):

	2025	2024	Change
Bonds.....	\$ 23	\$ (128)	\$ 151
Derivatives.....	(95)	(249)	154
Real estate.....	—	191	(191)
Common and preferred stocks.....	84	35	49
Limited partnerships	(106)	9	(115)
Other ¹	(122)	(21)	(101)
Total before OTTI and capital losses tax	(216)	(163)	(53)
OTTI ²	(227)	(350)	123
Capital gains tax expense	(39)	(1)	(38)
Net realized capital losses after-tax and before transfers to the IMR	(482)	(514)	32
Capital losses transferred to the IMR ³	109	374	(265)
Net realized capital losses after-tax	\$ (373)	\$ (140)	\$ (233)

1 Other includes foreign exchange gains and losses on funding agreements related to the Issuer's Notes.

2 OTTI losses are generally not subject to current tax treatment; however, current year tax includes benefits on current year OTTI on residential mortgage-backed securities and sales of other securities impaired in prior years.

3 Capital gains tax benefit transferred to the IMR was \$29 million and \$99 million for the nine months ended September 30, 2025 and 2024, respectively.

Realized capital gains on bonds of \$23 million for the nine months ended September 30, 2025 were primarily due to sales of corporate bonds, specifically an investment-grade bond exchange-traded fund ("ETF") that provides broader exposure to the corporate bond market, as well as corporate foreign agency bonds. The majority of these gains were transferred to the IMR. Realized capital losses on bonds of \$128 million for the nine months ended September 30, 2024 were primarily due to sales of treasury notes, corporate bonds and bond exchange traded funds. The majority of these losses were transferred to the IMR and the remaining losses were recorded to the asset valuation reserve ("AVR").

Realized capital losses on derivatives of \$95 million for the nine months ended September 30, 2025 were primarily due to the termination of derivative strategies used to manage duration and convexity. Of this amount, \$149 million was transferred to the IMR for the nine months ended September 30, 2025.

Realized capital losses on derivatives of \$249 million for the nine months ended September 30, 2024 were primarily due to the termination of derivative strategies used to hedge against a low-interest rate environment. Of this amount, \$297 million was transferred to the IMR. The losses that will amortize through the IMR are expected to be significantly offset by higher net investment income due to reinvestment at higher interest rates.

There were no realized capital gains (losses) on real estate for the nine months ended September 30, 2025. Realized capital gains on real estate of \$191 million for the nine months ended September 30, 2024 were primarily due to the sale of five properties in the multifamily and industry sectors.

Realized capital gains on common and preferred stocks of \$84 million for the nine months ended September 30, 2025 were primarily due to the sale of ETFs tracking the S&P 500 Index and the disposition of New York Life's remaining shares in Max Financial Services Ltd. Realized capital gains on common and preferred stocks of \$35 million for the nine months ended September 30, 2024 were primarily due to partial sale of Max Financial Services Ltd.

Realized capital losses on LP interests of \$106 million for the nine months ended September 30, 2025 were primarily due to the sale of two properties held within NYLIFE Office Holdings, an LP vehicle used for commercial real estate investments.

The following table shows the distribution of OTTI and the year-over-year change in OTTI by asset type for the nine months ended September 30, 2025 and 2024 (in millions):

	2025	2024	Change
Bonds	\$ (69)	\$ (76)	7
Limited partnerships	(113)	(137)	24
Real estate	(20)	—	(20)
Common and preferred stocks	(4)	(2)	(2)
Mortgage loans	(3)	(107)	104
Other invested assets	(18)	(28)	10
Total OTTI	\$ (227)	\$ (350)	123

OTTI on bonds of \$69 million for the nine months ended September 30, 2025 was primarily related to corporate bonds in the chemical, cable & media, and retail sectors facing stress from elevated interest rates, ongoing declines in traditional cable TV subscriptions, and heightened competition. OTTI on bonds of \$76 million for the nine months ended September 30, 2024 was primarily due to credit impairments in the healthcare, paper and packaging, chemical, cable and media sectors.

OTTI for LPs was \$113 million and \$137 million for the nine months ended September 30, 2025 and 2024, respectively. In both periods, OTTI was primarily driven by leveraged buyouts approaching the end of their lifecycle. In 2025, additional OTTI was recognized related to two real estate office sector LPs impacted by remote and hybrid work trends. Certain LPs record expenses and fees accumulated over the life of the partnership as unrealized losses. Therefore, when the partnership is at the end of its lifecycle such losses are realized and recorded as OTTI.

OTTI on real estate of \$20 million for the nine months ended September 30, 2025 was primarily due to an office building with low occupancy.

OTTI on mortgage loans of \$3 million and \$107 million for the nine months ended September 30, 2025 and 2024, respectively, was primarily due to impairments in the office sector.

Financial Position – At September 30, 2025 Compared to December 31, 2024

Assets

New York Life’s total assets at September 30, 2025 were \$255,790 million, which was \$10,889 million, or 4%, higher than the \$244,901 million reported at December 31, 2024. The increase was primarily reflected in the following assets:

- \$10,681 million higher cash and invested assets primarily driven by the investment of operating cash flow with the increase primarily in fixed income investments.

Liabilities

New York Life’s total liabilities, including Asset Valuation Reserve (“AVR”), at September 30, 2025 were \$228,979 million, which was \$10,505 million, or 5%, higher than the \$218,474 million reported at December 31, 2024. The increase is primarily reflected in the following liabilities:

- \$11,430 million increase in policy reserves and deposit funds is primarily driven by higher deposits in funding agreements related to issuances of Notes under the Program and Federal Home Loan Bank funding agreements as well as growth and aging of the inforce, particularly in whole life products. The table below presents policy reserves and deposit funds by business operation at September 30, 2025 and December 31, 2024 (\$ in millions):

	2025	2024	Change	
			\$	%
Life Insurance Solutions	\$ 99,860	\$ 96,432	\$ 3,428	4 %
New York Life Direct.....	3,777	3,691	86	2
Group Membership.....	2,149	2,133	16	1
LTC.....	5,008	4,773	235	5
Closed Block Reinsurance.....	4,141	4,322	(181)	(4)
Individual Disability Insurance.....	4	3	1	—
Total Insurance Business	114,939	111,354	3,585	3
Institutional Annuities	78,670	71,333	7,337	10
Retail Annuities	4,516	4,008	508	13
Total Annuities Business	83,186	75,341	7,845	10
Total	\$ 198,125	\$ 186,695	\$ 11,430	6 %

Statutory Surplus

Statutory surplus was \$26,811 million at September 30, 2025, an increase of \$384 million, or 1%, compared to the \$26,427 million reported at December 31, 2024. The main drivers of the change in New York Life’s statutory surplus are presented in the following table (in millions):

	<u>2025</u>
Beginning surplus	\$ 26,427
Net loss	(118)
Change in net unrealized capital gains/(losses) ¹	702
Change in deferred taxes ^{1,2}	(81)
Change in AVR	(209)
Change in nonadmitted assets ^{2,3}	(196)
Pension and post-retirement impacts ³	325
Change in surplus as a result of reinsurance	(39)
Ending surplus	26,811
AVR	4,797
Surplus and AVR⁴	\$ 31,608

1 Deferred tax benefit on change in net unrealized capital losses of \$17 million was reclassified to “Change in deferred taxes.”

2 An increase in nonadmitted deferred income taxes of \$206 million was reclassified to “Change in deferred taxes.”

3 A decrease in nonadmitted prepaid pension assets of \$74 million was reclassified to “Pension and post-retirement impacts.”

4 Consolidated statutory surplus and AVR, which includes the AVR of New York Life’s wholly owned U.S. insurance subsidiaries totaled \$34,008 million at September 30, 2025.

Change in Net Unrealized Capital Gains/(Losses)

The following table shows the components of the change in net unrealized capital gains/(losses) at September 30, 2025 compared to December 31, 2024 (in millions):

	<u>2025</u>
Affiliated:	
Domestic insurance subsidiaries:	
Operations	\$ 585
Amortization of goodwill ¹	(314)
Total domestic insurance subsidiaries	271
Asset management subsidiaries	371
Insurance subsidiary in Mexico and other	140
Total affiliated	782
Unaffiliated:	
Common stocks	(39)
Other invested assets	48
Mortgage loans	(64)
Other	(25)
Total unaffiliated	(80)
Total change in net unrealized capital gains/(losses)	\$ 702

¹ Goodwill associated with the acquisition of GBS in 2020.

The \$585 million increase in net unrealized capital gains related to domestic insurance operations was primarily driven by favorable performance in LINA resulting from strong underwriting margins.

Change in Deferred Taxes

The following table shows the components of the change in deferred taxes at September 30, 2025 compared to December 31, 2024 (in millions):

	<u>2025</u>
Deferred income tax benefit on operating results	\$ 108
Deferred tax benefit on change in net unrealized capital losses	17
Subtotal	125
Increase in nonadmitted deferred income taxes	(206)
Total change in deferred taxes	\$ (81)

Change in AVR

The AVR liability represents a portion of New York Life's surplus set aside to offset potential non-interest related investment losses. Changes in the AVR are recorded directly to surplus. The AVR liability is based on a formula prescribed by the National Association of Insurance Commissioners (the "NAIC") and is largely influenced by the size and quality of the investment portfolio. Changes in the AVR are driven by non-interest related gains and losses on the investment portfolio and an annual contribution based on factors set by the NAIC. Factors are also used to set a reserve objective and a maximum reserve. The AVR liability increased by \$209 million at September 30, 2025 compared to December 31, 2024, which reduced surplus and is currently at its maximum reserve.

Change in Nonadmitted Assets

Certain assets are not allowed as admitted assets in accordance with SAP. Generally, these are assets with economic value, but which cannot be readily used to pay policyholder obligations. New York Life had a net increase in nonadmitted assets that resulted in a decrease to surplus of \$196 million during the nine months ended September 30, 2025. The increase was primarily due to the change in nonadmitted assets related to investment in two wholly owned subsidiaries, NYL Investors LLC and Seguros Monterrey. This was partially offset by the change in nonadmitted goodwill associated with the GBS acquisition (see “—Change in Net Unrealized Capital Gains/(Losses)”).

Pension and Post-retirement Impacts

The calculation of pension and other post-retirement benefits obligations requires management to select demographic and economic assumptions that affect the reported amounts of assets and liabilities at December 31 of each year. Assumptions include, but are not limited to, interest rates, return on plan assets, mortality, withdrawal and retirement rates, and healthcare cost trend rate. The selected actuarial assumptions comply with the NAIC guidance, which requires New York Life to use its best estimate for each assumption, and are reviewed regularly for reasonableness, comparing assumed results to actual plan experience with adjustments made when necessary. New York Life uses a December 31 measurement date for these plans, as required.

Pension and post-retirement related impacts reported as a direct adjustment to surplus do not include the expenses (annual service costs, amortization of unrecognized actuarial losses and prior service costs/(credits)) reported in net gain/(loss) from operations. These adjustments increased surplus by \$325 million.

Liquidity Sources and Requirements

Liquidity Sources

New York Life's cash inflows from its insurance activities include life insurance premiums, annuity considerations, funding agreements, GICs and deposit funds. New York Life's cash inflows from investments result from proceeds on sales, interest payments, repayments of principal, maturities of invested assets and investment income. The following table sets forth the total available liquidity of New York Life from liquid assets and other funding sources at the end of the specified periods (in millions). Liquid assets include cash and cash equivalents, short-term investments and publicly traded securities, excluding assets that are pledged or otherwise committed. Other funding sources includes the available capacity at short-term borrowing facilities.

New York Life's Available Liquidity at Market Value (in millions)

	<u>September 30, 2025</u>	<u>December 31, 2024</u>
Cash and short-term investments:		
Cash and cash equivalents	\$ 3,357	\$ 3,960
Short-term investments	1,030	621
Less: securities lending and other short-term liabilities	(1,511)	(1,829)
Net cash and short-term investments	2,876	2,752
Liquid bonds:		
U.S. government and agency bonds	5,090	5,504
Public corporate investment-grade bonds & collateralized mortgage obligations	59,925	57,554
Liquid bonds	65,015	63,058
Equities:		
Public equities	323	350
Total liquid assets	68,214	66,160
Other funding sources:		
Bank facility/commercial paper capacity	2,926	3,000
Federal Home Loan Bank available capacity ¹	8,780	8,514
Total other funding sources	11,706	11,514
Total available liquidity	\$ 79,920	\$ 77,674

¹ Available capacity represents 5% of New York Life's total admitted assets. At September 30, 2025, New York Life's borrowing capacity with the Federal Home Loan Bank of New York was \$12,789 million, of which \$4,009 million had been used. At December 31, 2024, New York Life's borrowing capacity with the Federal Home Loan Bank of New York Life was \$12,245 million, of which \$3,731 million had been used.

New York Life's U.S. insurance subsidiaries are subject to certain insurance department regulatory restrictions as to the payment of dividends to New York Life. These restrictions pose no short-term or long-term liquidity concerns for New York Life, as it does not rely on subsidiary dividends as a significant source of liquidity.

Liquidity Uses

New York Life's principal cash outflows primarily relate to the payment of liabilities associated with its various life insurance, annuity and group pension (GICs and funding agreements) products, operating expenses and income taxes. Liabilities arising from New York Life's insurance activities primarily relate to benefit payments, policy surrenders, withdrawals from GICs and maturities of funding agreements, and loans and dividends to policyholders. See "Management's Discussion and Analysis of Financial Condition and Results of Operations—Investment Risk Management" for a discussion of liquidity risk.

A primary liquidity concern with respect to life insurance and annuity products is the risk of early policyholder and contract holder withdrawals. New York Life includes provisions in certain of its contracts that are designed to limit withdrawals from general account institutional pension products (group annuities, GICs and certain deposit fund liabilities) sold to employee benefit plan sponsors. Such provisions include surrender charges, market value adjustments and prohibitions or restrictions on withdrawals. New York Life closely monitors its liquidity requirements in order to match cash inflows with expected cash outflows and employs an asset/liability management approach tailored to the specific requirements of each product line based upon the return objectives, risk tolerance, liquidity, tax and regulatory requirements of the underlying products. It also regularly conducts liquidity stress tests and monitors early warning indicators of potential liquidity issues.

New York Life participates in a securities lending program for its general account whereby fixed income securities are loaned to third parties, primarily major brokerage firms and commercial banks. The borrowers of its securities provide New York Life with collateral, typically in cash. New York Life separately manages this collateral and invests such cash collateral in a portfolio of highly rated fixed income securities with short maturities. Securities on loan under the program could be returned to New York Life by the borrowers, or New York Life could call such securities at any time. Returns of loaned securities would require New York Life to return the cash collateral associated with such loaned securities. New York Life was liable for cash collateral under its control of \$502 million at September 30, 2025 and \$685 million at December 31, 2024. See "Risk Factors—Risk Factors Relating to New York Life—New York Life's Securities Lending Program Subjects It to Potential Liquidity and Other Risks."

New York Life is committed to maintaining adequate capitalization for its insurance and non-insurance subsidiaries to fund growth opportunities and support new products, and, with respect to its U.S. insurance subsidiaries, to maintain targeted risk-based capital ("**RBC**") levels. In addition, New York Life may make loans to its affiliates to provide additional funds to meet the business needs of these entities. New York Life made capital contributions (net of returns of capital) of \$75 million to its insurance subsidiaries during the nine months ended September 30, 2025, and received returns of capital (net of capital contributions) of \$287 million from its insurance and non-insurance subsidiaries during the year ended December 31, 2024.

CERTAIN FINANCIAL AND ACCOUNTING MATTERS

Accounting Policies and Principles

Statutory Accounting Practices

The financial statements of New York Life included in this Offering Memorandum are presented in accordance with SAP prescribed or permitted by the NYSDFS. SAP differs from generally accepted accounting principles in the United States (“GAAP”) in that SAP is primarily designed to reflect the ability of the insurer to satisfy its obligations to policyholders, contract holders and beneficiaries, whereas in accordance with GAAP, revenues and expenses are recorded in financial reporting periods to match revenues and expenses and reflect the ongoing financial results of the insurer. For example, in accordance with SAP, commissions and other costs incurred in connection with acquiring new business are charged to operations in the year incurred, whereas in accordance with GAAP, certain of these expenses are deferred and amortized on a basis to match them against appropriate revenues.

In accordance with SAP, New York Life’s financial statements are not consolidated and investments in subsidiaries are generally shown at net equity value. Accordingly, the assets, liabilities and results of operations of New York Life’s subsidiaries are not consolidated with the assets, liabilities and results of operations, respectively, of New York Life. However, New York Life’s financial statements reflect, in New York Life’s assets, the net equity value of New York Life’s subsidiaries and, in New York Life’s surplus, the current year change in net equity value of subsidiaries, less contributions received from or returns of capital paid to New York Life, as an unrealized gain or loss on investments. Dividends declared by subsidiaries to New York Life are included in New York Life’s net investment income.

Discussion of Certain Differences between SAP and GAAP

The financial information of New York Life is presented in accordance with SAP. Statutory accounting is used by state insurance regulators to monitor the operations of insurance companies. Financial statements prepared in accordance with SAP as determined under New York Insurance Law vary from those prepared in accordance with GAAP in certain material respects, primarily as follows:

Investments

- debt securities must meet a principles-based bond definition (“PBBB”) in order to be reported as bonds in accordance with SAP, whereas a PBBB does not exist for GAAP;
- investments in bonds are generally carried at amortized cost or values as prescribed by the NYSDFS. Investments in bonds that do not meet the PBBB are generally reported at the lower of cost or market. In accordance with GAAP, investments in bonds that are classified as available for sale or trading are carried at fair value, with changes in fair value of bonds classified as available for sale reflected in equity, and changes in fair value of bonds classified as trading reflected in earnings;
- credit loss-related bond impairments that are deemed to be other than temporary are recorded as a direct write-down to the security without the ability to reverse those losses in the future if expected cash flows increase. In accordance with GAAP, estimated credit losses on bonds classified as available for sale are recorded through an allowance for credit losses subject to future reversals if expected cash flows increase;
- investments in subsidiaries, controlled and other affiliated entities as defined in Statements of Statutory Accounting Principles No. 97, “Investments in Subsidiary, Controlled and Affiliated Entities” (“SCAs”), including partnerships, limited liability companies and joint ventures, are accounted for under the equity method. Under the equity method, domestic insurance subsidiaries are recorded at their underlying audited statutory surplus. Nonpublic non-insurance subsidiaries and other controlled entities are

recorded at their underlying audited GAAP equity. Changes in the value of such investments are recorded as unrealized gains or losses. The earnings of such investments are recorded in net investment income only when dividends are declared. In accordance with GAAP, these investments are consolidated;

- investments in noncontrolled partnerships and limited liability companies are accounted for under the equity method in accordance with both SAP and GAAP. Under the statutory equity method, undistributed income and capital gains and losses for these investments are reported in surplus as unrealized gains or losses, whereas in accordance with GAAP, in many cases, for investment companies, unrealized gains and losses are included in net investment income;
- for investments in mortgage loans, specific valuation allowances are established for the excess carrying value of a mortgage loan over the estimated fair value of the collateral as an unrealized loss in surplus when it is probable that based on current information and events, New York Life will be unable to collect amounts due under the contractual terms of the loan agreement. In accordance with GAAP, a valuation allowance is established for expected credit losses. The valuation allowance in accordance with GAAP is based on historical experience, current economic conditions and reasonable and supportable forecasts;
- realized gains and losses resulting from changes in interest rates are deferred in the IMR and amortized into investment income over the remaining life of the investment sold, whereas in accordance with GAAP, the gains and losses are recognized in income at the time of sale;
- certain derivative instruments are carried at amortized cost, whereas in accordance with GAAP, all derivative instruments are carried at fair value;

Insurance Contracts

- contracts that have any mortality or morbidity risk, regardless of significance, and contracts with life contingent annuity purchase rate guarantees are classified as insurance contracts, whereas in accordance with GAAP, only contracts that have significant mortality or morbidity risk are classified as insurance contracts, otherwise they are accounted for in a manner consistent with the accounting for interest bearing or other financial instruments;
- payments received for universal and variable life insurance products, certain variable and fixed deferred annuities and group annuity contracts are reported as premium income and corresponding change in reserves, whereas GAAP would treat these payments as deposits to policyholders' account balances;
- the costs related to acquiring insurance contracts (principally commissions), policy issue expenses and sales inducements are charged to income in the period incurred, whereas in accordance with GAAP, these costs are deferred when related directly to successful sales and amortized over the periods benefited;
- life insurance and annuity reserves are based on different statutory methods and assumptions than they are in accordance with GAAP;
- reinsurance agreements are accounted for as reinsurance on a SAP and GAAP basis if certain risk transfer provisions have been met. SAP requires the reinsurer to assume insurance risk, regardless of the significance of the loss potential, whereas GAAP requires that there is a reasonable possibility that the reinsurer may realize significant loss from assuming insurance risk; assets and liabilities from reinsurance transactions are reported net of reinsurance, whereas in accordance with GAAP, assets and liabilities from reinsurance transactions are reported gross of reinsurance;

Taxes

- deferred income taxes exclude state income taxes and are admitted to the extent they can be realized within three years subject to a 15% limitation of capital and surplus with changes in the net deferred tax reflected as a component of surplus, whereas in accordance with GAAP, deferred income taxes include federal and state income taxes and changes in deferred taxes are reflected in either earnings or other comprehensive income;
- a tax loss contingency is required to be established if it is more likely than not that a tax position will not be sustained upon examination by taxing authorities. If a loss contingency is greater than 50% of the tax benefit associated with a tax position, the loss contingency is increased to 100%, whereas in accordance with GAAP the amount of the benefit for any uncertain tax position is the largest amount that is greater than 50% likely of being realized upon settlement;

Surplus

- an AVR based on a formula prescribed by the NAIC is established as a liability to offset potential non-interest related investment losses. Changes in the AVR are recorded directly to surplus, whereas in accordance with GAAP, no AVR is recognized;
- certain assets, such as investments in SCA entities that do not have audited financial statements, deferred taxes as noted above, intangible assets, overfunded pension plan assets, furniture and equipment, and unsecured receivables are considered nonadmitted and excluded from assets, whereas they are included in assets in accordance with GAAP subject to a valuation allowance, as appropriate;
- surplus notes are included as a component of surplus, whereas in accordance with GAAP, they are presented as a liability; and

Other

- goodwill held by an insurance company is admitted subject to a 10% limitation on surplus and amortized over the useful life of the goodwill, not to exceed 10 years, and goodwill held by non-insurance subsidiaries is assessed in accordance with GAAP, subject to certain limitations for holding companies and foreign insurance subsidiaries, whereas in accordance with the GAAP private company accounting alternative, goodwill is amortized over the useful life of the goodwill, not to exceed 10 years, and is tested for impairment, but it is not subject to the 10% limitation on equity.

The effects on the financial statements of the above variances between SAP as determined under New York Insurance Law and in accordance with GAAP are material to New York Life.

Adjustments for Impaired Investments

The cost basis of bonds and equity securities is adjusted for impairments in value deemed to be other-than-temporary, with the associated realized loss reported in net income. For a discussion of how New York Life determines whether an impairment is appropriate, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations—New York Life’s Investment Portfolio.”

Statutory Investment Reserves

SAP requires a life insurance company to maintain both an AVR and an IMR to absorb both realized and unrealized gains and losses on a portion of the life insurance company’s investments. The AVR is an investment reserve established to provide for default risk on fixed income assets and market value fluctuation on equity-type investments. The amount of the AVR is determined by formula, which considers the type of investment, the credit rating (where

applicable) and current year changes in realized and unrealized capital gains and losses (other than those resulting from changes in interest rates). Changes in the AVR are accounted for as direct increases or decreases in surplus.

The IMR applies to interest-sensitive investments including bonds, preferred stocks, mortgage-backed securities, asset-backed securities, mortgage loans and certain derivatives. The IMR is designed to capture the after-tax capital gains or losses which are realized upon the sale of such investments and which result from changes in the overall level of interest rates. The captured after-tax net realized gains or losses are then amortized into income. In accordance with the NAIC's interim statutory accounting guidance, insurers are allowed to admit negative IMR (i.e., when deferred cumulative realized losses exceed cumulative realized gains) as special surplus for admitted disallowed IMR up to 10% of its capital and surplus as required to be shown on the balance sheet of the statutory financial statements most recently filed by such insurer with its domiciliary state insurance regulator, adjusted to exclude any net positive goodwill, electronic database processing equipment and operating system software, net deferred tax assets and admitted net negative IMR. Only insurers with a risk-based capital greater than 300% authorized control level can admit negative IMR. Most of New York Life's admitted disallowed IMR relates to realized losses on derivatives. New York Life uses derivatives to hedge reinvestment risk by locking in a yield. The amortization of the IMR derivative losses is offset by higher investment income earned on new bonds.

Dividends to Policyholders

New York Life annually determines the amount of dividends payable to eligible policyholders. These dividends have the effect of reducing the cost of insurance to policyholders and should be distinguished from the dividends paid on shares of capital stock by other types of business corporations or by stock life insurance companies. Policies on which such dividends may be payable are referred to as participating policies; policies on which such dividends are not payable are referred to as non-participating policies.

Annually, the Board of Directors approves the divisible surplus¹ of New York Life to be paid out to eligible policyholders in accordance with an actuarially determined dividend scale. New York Life has discretion, subject to statutory requirements as to the source of dividends, to vary the amount of dividends payable to policyholders, even many years after the issuance of a particular policy. In determining the policyholder dividends payable in any year, the Board of Directors considers, among other things, the amounts necessary to meet New York Life's future policy obligations, maintain reserves and operate the business. To the extent authorized by the Board of Directors, New York Life has the right to continue to declare policyholder dividends and to make dividend payments on its participating policies.

Policy Reserves

Life insurance companies price their insurance products based upon assumptions regarding certain future events, including investment income, expenses incurred and use of mortality and morbidity tables. SAP prescribes methods for providing for future benefits to be paid on a conservative basis, primarily by charging current operations with amounts necessary to establish appropriate reserves for anticipated future claims. Thus, under applicable state law, New York Life must maintain reserves in amounts which are actuarially calculated to be sufficient to meet its various policy and contract obligations as they become due. Such reserves appear as liabilities on New York Life's financial statements.

New York Life is required under the New York Insurance Law to conduct annually an analysis of the sufficiency of all life insurance and annuity statutory reserves. New York Life conducts its annual analysis as of December 31, see "Regulation and Supervision—Insurance Regulation—Policy and Contract Reserve Sufficiency Analysis."

¹ Divisible surplus is the portion of New York Life's total surplus that is available, following each year's operations, for distribution in the form of dividends.

Reinsurance

New York Life uses a variety of reinsurance agreements with insurers to control its loss exposure. Generally, these agreements are structured either on an automatic basis, where all risks meeting prescribed criteria are automatically covered, or on a facultative basis, where the reinsurer must accept the specific reinsurance risk before the reinsurer becomes liable on that risk. The amount of each risk retained by New York Life on a facultative basis depends on its evaluation of the specific risk, its maximum retention limits and the amount of reinsurance available.

Under the terms of the reinsurance agreements, the reinsurers will be liable to reimburse New York Life for the ceded amount in the event a claim on a reinsured policy is paid. New York Life remains primarily liable for all claims payable on reinsured policies, even if the reinsurer fails to meet its obligations under the reinsurance agreement. New York Life routinely collects amounts due from its reinsurers on a timely basis. For more information, see “Description of the Business of the Company—Reinsurance.”

New York Life is a party to a reinsurance agreement (the “**Closed Block Reinsurance**”) with John Hancock Life Insurance Company (U.S.A.) and one of its affiliates (“**John Hancock**”) in which New York Life assumes on a coinsurance basis 100% of John Hancock’s obligations and liabilities under the policies included in the closed block of participating whole life policies established in connection with the demutualization of John Hancock Mutual Life Insurance Company (the “**Closed Block**”). New York Life retrocedes 40% of those obligations and liabilities to John Hancock on a funds-withheld arrangement. The assets received from this transaction are held in a reinsurance trust as security for New York Life’s obligations to John Hancock and are contractually restricted. The majority of such assets are allocated to the Closed Block and are held for the exclusive benefit of the policies included in the Closed Block.

The insurance-related revenue from the Closed Block policies, including net investment income from the assets allocated to the Closed Block, after satisfying certain related expenses and taxes, inure solely to the benefit of those reinsured policyholders and will not be available to New York Life’s policyholders. Dividends for the Closed Block are approved by John Hancock.

Effective December 31, 2023, New York Life entered into a strategic indemnity reinsurance agreement on a coinsurance with funds withheld basis (the “**Term Reinsurance Agreement**”) with Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft (“**Munich Re**”). Under the Term Reinsurance Agreement, New York Life ceded on a quota share basis 85% of all the risks under certain term life policies and respective riders issued by New York Life between January 1, 2000 and December 31, 2019. New York Life pays Munich Re an annual risk and profit charge which will decrease over time. New York Life receives from Munich Re a quarterly experience refund if the experience refund formula is positive.

Separate Accounts

Under state insurance laws, insurers are permitted to establish separate investment accounts in which assets backing certain policies, including certain group annuity contracts, are held. The investments in each separate account (which may be pooled or customer-specific) are maintained separately from those in other separate accounts and the general account. Generally, the investment results of the separate account assets pass through to separate account policyholders and contract holders, so that an insurer derives management and other fees from, but bears no investment risk on, these assets. In separate accounts for products with minimum interest rate guarantees, the risk that the investment results of the separate account assets will not meet the minimum rate guaranteed on these products is borne by the insurer.

STATUTORY CAPITALIZATION OF NEW YORK LIFE

New York Life is a mutual insurance company incorporated under the laws of the State of New York, United States. New York Life was incorporated on May 21, 1841 under the name Nautilus Insurance Company, was licensed to transact business in the State of New York on April 17, 1845 and changed its name to New York Life Insurance Company on April 5, 1849. The U.S. federal employer identification number of New York Life is 13-5582869. The registered office of New York Life is 51 Madison Avenue, New York, New York 10010. The telephone number of New York Life is +1 (800) 692-3086.

As a mutual company, New York Life has no capital stock and no shareholders. New York Life’s participating policyholders generally have certain rights to receive policy dividends, and they and certain other policyholders may have rights to receive distributions in a proceeding for its rehabilitation, liquidation or dissolution. Policyholders also have certain rights to vote in the election of directors as provided by New York law.

New York Life’s balance sheet includes its surplus and an AVR. The amount by which the admitted assets of New York Life exceed its liabilities is referred to as surplus. The AVR stabilizes surplus from fluctuations in the value of the investment portfolio (see “Certain Financial and Accounting Matters—Accounting Policies and Principles—Statutory Investment Reserves”).

The following table sets forth the capitalization of New York Life at September 30, 2025. The AVR is included in the following table even though such reserve is shown as a liability on New York Life’s balance sheet. This treatment is consistent with the general view of the insurance industry. In addition, this reserve is included as part of total adjusted capital for RBC purposes.

	September 30, 2025 <hr style="border: 0.5px solid black;"/> (in millions)
Total Short-Term Debt (less than 1 year)	\$ 473
AVR	\$ 4,797
Surplus:	
Surplus notes	4,234
Special surplus for admitted disallowed IMR ¹	924
Unassigned funds	21,653
Surplus and AVR	\$ 31,608

¹ See “Certain Financial and Accounting Matters—Accounting Policies and Principles—Statutory Investment Reserves.”

SELECTED HISTORICAL STATUTORY FINANCIAL INFORMATION OF NEW YORK LIFE

The table presented below sets forth selected financial information for New York Life. Prospective investors should read it in conjunction with “Certain Financial and Accounting Matters” and New York Life’s Statutory Financial Statements included in the Offering Memorandum. The selected financial information for New York Life’s Statement of Financial Position and Statement of Operations at or for the years ended December 31, 2024, 2023 and 2022 has been derived from the annual audited statutory financial statements. The selected financial information for New York Life at or for the nine months ended September 30, 2025 and 2024 has been derived from the quarterly unaudited statutory financial statements.

The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements. Actual results may differ from estimates. Historical results are not necessarily indicative of results for any future period.

	At or for the Nine Months Ended September 30,		At or for the Year Ended December 31,		
	2025	2024	2024	2023	2022
	(in millions)				
Statement of Operations Data:					
Total income	\$ 21,023	\$ 20,156	\$ 27,193	\$ 23,838	\$ 25,880
Dividends to policyholders ¹	2,045	1,844	2,651	2,389	2,131
Net (loss)/gain from operations	255	844	846	70	170
Net (loss)/income	(118)	704	470	28	15
Statement of Financial Position Data:					
Total assets	\$ 255,790	\$ 243,664	\$ 244,901	\$ 231,902	\$ 222,781
Total liabilities	\$ 228,979	\$ 217,393	\$ 218,474	\$ 206,608	\$ 198,894
Surplus:					
Surplus notes	4,234	4,233	4,233	4,232	4,232
Special surplus for admitted disallowed IMR ²	924	824	804	435	—
Unassigned funds	21,653	21,214	21,390	20,627	19,655
Surplus	26,811	26,271	26,427	25,294	23,887
Asset valuation reserve ³	4,797	4,585	4,588	4,513	4,235
Surplus and asset valuation reserve	\$ 31,608	\$ 30,856	\$ 31,015	\$ 29,807	\$ 28,122
Other Data:					
Equity investment in subsidiaries ⁴	\$ 15,550	\$ 14,765	\$ 14,738	\$ 14,373	\$ 13,617

1 Dividends to policyholders (excluding dividends on assumed reinsurance) are discretionary and subject to the approval of the Board of Directors and dividends for the Closed Block are approved by the ceding company.

2 See “Certain Financial and Accounting Matters—Accounting Policies and Principles—Statutory Investment Reserves.”

3 Included in Total liabilities above but are treated as part of adjusted capital in the calculation of RBC.

4 Included in Total assets above.

NEW YORK LIFE INSURANCE COMPANY
CONDENSED STATUTORY FINANCIAL STATEMENTS
For the quarterly period ended September 30, 2025

NEW YORK LIFE INSURANCE COMPANY
CONDENSED STATUTORY STATEMENTS OF FINANCIAL POSITION
(UNAUDITED)

	September 30,	December 31,
	2025	2024
	(in millions)	
Assets		
Bonds	\$ 151,733	\$ 146,462
Common and preferred stocks	14,687	14,092
Mortgage loans	27,018	23,786
Policy loans	14,613	13,898
Other invested assets	15,224	14,231
Cash, cash equivalents and short-term investments	4,184	4,231
Derivatives	1,455	1,489
Real estate	2,450	2,343
Total cash and invested assets	231,364	220,532
Deferred and uncollected premiums	1,962	1,689
Investment income due and accrued	2,344	2,380
Admitted disallowed interest maintenance reserve	925	804
Other assets	8,117	7,862
Separate accounts assets	11,078	11,634
Total assets	\$ 255,790	\$ 244,901
Liabilities and surplus		
Liabilities:		
Policy reserves	\$ 146,212	\$ 142,176
Deposit funds	51,913	44,519
Dividends payable to policyholders	2,738	2,608
Policy claims	1,068	802
Borrowed money	473	450
Amounts payable under security lending agreements	504	688
Derivatives	686	1,271
Funds held under coinsurance	3,334	3,476
Other liabilities	6,176	6,262
Asset valuation reserve	4,797	4,588
Separate accounts liabilities	11,078	11,634
Total liabilities	228,979	218,474
Surplus:		
Surplus notes	4,234	4,233
Special surplus for admitted disallowed interest maintenance reserve	924	804
Unassigned surplus	21,653	21,390
Total surplus	26,811	26,427
Total liabilities and surplus	\$ 255,790	\$ 244,901

NEW YORK LIFE INSURANCE COMPANY
CONDENSED STATUTORY STATEMENTS OF OPERATIONS
(UNAUDITED)

	Nine Months Ended	
	September 30,	
	2025	2024
	(in millions)	
Income		
Premiums	\$ 13,821	\$ 12,851
Net investment income	7,005	7,135
Other income	197	170
Total income	<u>21,023</u>	<u>20,156</u>
Benefits and expenses		
Benefit payments:		
Death benefits	3,359	3,344
Annuity benefits	1,292	1,227
Health and disability insurance benefits	261	258
Surrender benefits	2,057	1,909
Payments on matured contracts	4,765	3,744
Other benefit payments	1,338	1,036
Total benefit payments	<u>13,072</u>	<u>11,518</u>
Additions to reserves	4,123	4,254
Net transfers from separate accounts	(1,058)	(1,143)
Adjustment in funds withheld	103	107
Operating expenses	2,601	2,712
Total benefits and expenses	<u>18,841</u>	<u>17,448</u>
Gain from operations before dividends to policyholders and federal and foreign income taxes	2,182	2,708
Dividends to policyholders	2,045	1,844
(Loss)/gain from operations before federal and foreign income taxes	137	864
Federal and foreign income taxes	(118)	20
Net (loss)/gain from operations	<u>255</u>	<u>844</u>
Net realized capital (losses)/gains, after tax and transfers to interest maintenance reserve	(373)	(140)
Net (loss) income	<u>\$ (118)</u>	<u>\$ 704</u>

NEW YORK LIFE INSURANCE COMPANY
CONDENSED STATUTORY STATEMENTS OF CHANGES IN SURPLUS
(UNAUDITED)

	September 30,	December 31,
	2025	2024
	(in millions)	
Surplus, beginning of year	\$ 26,427	\$ 25,294
Net income	(118)	470
Change in liability for pension and post-retirement plans	251	162
Change in asset valuation reserve	(209)	(75)
Change in nonadmitted assets	(328)	577
Change in net deferred income tax	108	334
Change in surplus as a result of reinsurance	(39)	(14)
Change in net unrealized capital gains on investments	1,032	97
Goodwill amortization	(313)	(418)
Surplus, end of period	\$ 26,811	\$ 26,427

NEW YORK LIFE INSURANCE COMPANY
CONDENSED STATUTORY STATEMENTS OF CASH FLOWS
(UNAUDITED)

	Nine Months Ended	
	September 30,	
	2025	2024
	(in millions)	
Cash flows from operating activities:		
Premiums received	\$ 13,536	\$ 12,610
Net investment income received	6,959	6,530
Other	158	304
Total received	<u>20,653</u>	<u>19,444</u>
Benefits and other payments	11,564	10,323
Net transfers from separate accounts	(1,054)	(1,113)
Operating expenses	2,533	2,578
Dividends to policyholders	1,914	1,707
Federal income taxes paid	(2)	335
Total paid	<u>14,955</u>	<u>13,830</u>
Net cash from operating activities	<u>5,698</u>	<u>5,614</u>
Cash flows from investing activities:		
Proceeds from investments sold	14,641	13,954
Proceeds from investments matured or repaid	12,165	9,971
Cost of investments acquired	(35,576)	(31,654)
Net change in policy loans and premium notes	(716)	(753)
Net cash used in investing activities	<u>(9,486)</u>	<u>(8,482)</u>
Cash flows from financing and miscellaneous activities:		
Borrowed funds	(59)	(15)
Net inflows from deposit contracts	4,619	4,400
Other miscellaneous uses	(820)	(774)
Net cash from financing and miscellaneous activities	<u>3,740</u>	<u>3,611</u>
Net (decrease)/increase in cash, cash equivalents and short-term investments	(48)	743
Cash, cash equivalents and short-term investments, beginning of year	4,231	3,595
Cash, cash equivalents and short-term investments, end of period	<u>\$ 4,183</u>	<u>\$ 4,338</u>

NEW YORK LIFE INSURANCE COMPANY
NOTES TO CONDENSED STATUTORY FINANCIAL STATEMENTS
(UNAUDITED)

NOTE 1 - NATURE OF OPERATIONS

BASIS OF PRESENTATION

The accompanying financial statements of New York Life Insurance Company ("the Company") have been prepared using accounting practices prescribed by the New York State Department of Financial Services ("NYSDFS" or "the Department").

The Department recognizes only statutory accounting practices prescribed or permitted by the State of New York for determining and reporting the financial position and results of operations of an insurance company and for determining its solvency under New York Insurance Law. The National Association of Insurance Commissioners' ("NAIC") Accounting Practices and Procedures Manual ("NAIC SAP") has been adopted as a component of prescribed practices by the State of New York. Prescribed statutory accounting practices include state laws and regulations. Permitted statutory accounting practices encompass accounting practices that are not prescribed; such practices differ from state to state, may differ from company to company within a state, and may change in the future. The Company has no permitted practices.

A reconciliation of the Company's net income and capital and surplus at September 30, 2025 and December 31, 2024 between practices prescribed or permitted by the State of New York and NAIC SAP is shown below (in millions):

	<u>SSAP #</u>	<u>F/S Page</u>	<u>F/S Line #</u>	<u>2025</u>	<u>2024</u>
<u>Net Income</u>					
(1) Net income, New York State basis (Page 4, Line 35, Columns 1 & 3)	XXX	XXX	XXX	\$ (118)	\$ 470
(2) State prescribed practices that increase/(decrease) NAIC SAP:					
NYSDFS Regulation No. 213 principle-based reserving and No. 151 minimum life and annuity reserves*	51R	3	1	(37)	(65)
NYSDFS Circular Letter No. 11 (2010) impact on deferred premiums**	61	2, 4, 5	15.2, 1, 1	16	14
NYSDFS Seventh Amendment to Regulation No. 172 impact on admitted unearned reinsurance premium***	61	2, 4, 5	15.2, 1, 1	(6)	(3)
(3) State permitted practices that increase/(decrease) NAIC SAP:				—	—
(4) Net income, NAIC SAP (1-2-3=4)	XXX	XXX	XXX	<u>\$ (91)</u>	<u>\$ 524</u>
<u>Capital and Surplus</u>					
(5) Statutory capital and surplus, New York State basis (Page 3, Line 38, Columns 1 & 2)	XXX	XXX	XXX	\$ 26,811	\$ 26,427
(6) State prescribed practices that increase/(decrease) NAIC SAP:					
NYSDFS Regulation No. 213 principle-based reserving and No. 151 minimum life and annuity reserves*	51R	3	1	(258)	(220)
NYSDFS Circular Letter No. 11 (2010) impact on deferred premiums**	61	2, 4, 5	15.2, 1, 1	(94)	(110)
NYSDFS Seventh Amendment to Regulation No. 172 impact on admitted unearned reinsurance premium***	61	2, 4, 5	15.2, 1, 1	51	58
(7) State permitted practices that increase/(decrease) NAIC SAP:				—	—
(8) Capital and surplus, NAIC SAP (5-6-7=8)	XXX	XXX	XXX	<u>\$ 27,112</u>	<u>\$ 26,699</u>

* NYSDFS Regulation 213 subjects principle-based valuations as prescribed by the valuation manual to minimum New York State requirements; NYSDFS Regulation 151 prescribes rules and guidelines for performing valuations of annuity, single premium life insurance, guaranteed interest contract and other deposit reserves.

** NYSDFS Circular Letter No. 11 (2010) clarified the accounting for deferred premium assets when reinsurance is involved.

*** NYSDFS Regulation 172 was amended to allow for the admission of an unearned reinsurance premium asset.

NEW YORK LIFE INSURANCE COMPANY
NOTES TO CONDENSED STATUTORY FINANCIAL STATEMENTS
(UNAUDITED)

Note 2 - Fair Value Measurements

A. The Company's financial assets and liabilities carried at fair value have been classified, for disclosure purposes, based on a hierarchy defined by SSAP No. 100, "Fair Value Measurements". Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. This guidance establishes a framework for measuring fair value that includes a hierarchy used to classify the inputs used in measuring fair value. The hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels. The level in the fair value hierarchy within which the fair value measurement falls is determined based on the lowest level input that is significant to the fair value measurement.

(1) The levels of the fair value hierarchy are based on the inputs to the valuation as follows:

Level 1 Fair value is based on unadjusted quoted prices for identical assets or liabilities in an active market. Active markets are defined as a market in which many transactions occur with sufficient frequency and volume to provide pricing information on an ongoing basis.

Level 2 Observable inputs other than level 1 prices, such as quoted prices in active markets for similar assets or liabilities; quoted prices in markets that are not active for identical or similar assets or liabilities, or other model driven inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Valuations are generally obtained from third-party pricing services for identical or comparable assets or liabilities or through the use of valuation methodologies using observable market inputs.

Level 3 Instruments whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management's own assumptions in pricing the asset or liability. Pricing may also be based upon broker quotes that do not represent an offer to transact. Prices are determined using valuation methodologies such as option pricing models, discounted cash flow models and other similar techniques. Non-binding broker quotes, which are utilized when pricing service information is not available, are reviewed for reasonableness based on the Company's understanding of the market, and are generally considered Level 3. To the extent the internally developed valuations use significant unobservable inputs, they are classified as Level 3.

NEW YORK LIFE INSURANCE COMPANY
NOTES TO CONDENSED STATUTORY FINANCIAL STATEMENTS
(UNAUDITED)

The following table represents the balances of assets and liabilities measured at fair value or net asset value ("NAV") as of September 30, 2025 (in millions):

	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Net Asset Value (NAV)	Total
a. Assets at fair value					
Redeemable preferred stocks	\$ —	\$ —	\$ —	\$ —	\$ —
1. Preferred stocks	—	39	125	—	164
2. Bonds					
Issuer Credit Obligations	23	6	4	—	33
Asset-Backed Securities	—	9	—	—	9
Total bonds	23	15	4	—	42
3. Common stocks	267	—	259	—	526
4. Derivative assets					
Interest rate swaps	—	117	—	—	117
Foreign currency swaps	—	65	—	—	65
Inflation swaps	—	3	—	—	3
Interest rate options	—	9	—	—	9
Foreign currency forwards	—	2	—	—	2
Total derivative assets	—	196	—	—	196
5. Separate accounts assets	469	2,764	3	1,136	4,372
6. Other invested assets	—	54	14	—	68
Total assets at fair value	\$ 759	\$ 3,068	\$ 405	\$ 1,136	\$ 5,368
b. Liabilities at fair value					
1. Derivative liabilities					
Interest rate swaps	\$ —	\$ 163	\$ —	\$ —	\$ 163
Foreign currency swaps	—	8	—	—	8
Inflation swaps	—	19	—	—	19
Foreign currency forwards	—	6	—	—	6
Total derivative liabilities	—	196	—	—	196
2. Separate accounts liabilities - derivatives ¹	—	—	—	—	—
Total liabilities at fair value	\$ —	\$ 196	\$ —	\$ —	\$ 196

¹ Separate accounts contract holder liabilities are not included in the table as they are reported at contract value and not fair value in the Company's Annual Statement.

NEW YORK LIFE INSURANCE COMPANY
NOTES TO CONDENSED STATUTORY FINANCIAL STATEMENTS
(UNAUDITED)

(2) The table below presents a rollforward of level 3 assets and liabilities for the three months ended September 30, 2025 (in millions):

	Balance at 07/01/2025	Transfers into Level 3	Transfers out of Level 3	Total gains or (losses) included in Net Income	Total gains or (losses) included in Surplus	Purchases	Issuances	Sales	Settlements	Balance at 09/30/2025
Assets:										
Preferred stocks	\$ 111	\$ 7	\$ (1)	\$ —	\$ 6	\$ 2	\$ —	\$ —	\$ —	\$ 125
Bonds										
Issuer Credit Obligations	5	—	(1)	—	—	—	—	—	—	4
Asset-Backed Securities	—	—	—	—	—	—	—	—	—	—
Total bonds	5	—	(1)	—	—	—	—	—	—	4
Common stocks	234	11	—	—	6	9	—	(1)	—	259
Derivatives	—	—	—	—	—	—	—	—	—	—
Separate accounts assets ¹	5	—	—	—	1	—	—	(3)	—	3
Other invested assets	43	—	(38)	—	—	9	—	—	—	14
Total Assets:	\$ 398	\$ 18	\$ (40)	\$ —	\$ 13	\$ 20	\$ —	\$ (4)	\$ —	\$ 405
Liabilities:										
Derivatives	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —
Total Liabilities	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —

¹ The total gains or (losses) included in surplus for separate accounts assets are offset by an equal amount for separate accounts liabilities, which results in a net zero impact on surplus for the Company.

Transfers between levels

Transfers between levels may occur due to changes in valuation sources, or changes in the availability of market observable inputs, which generally are caused by changes in market conditions such as liquidity, trading volume or bid-ask spreads, or as a result of a security measured at amortized cost at the beginning of the period, but measured at estimated fair value at the end of the period, or vice versa due to a ratings downgrade or upgrade.

Transfers into and out of Level 3

The Company's basis for transferring assets and liabilities into and out of Level 3 is based on changes in the observability of data, a change in the security's measurement or changes in redemption restrictions of certain separate account investments.

Transfers into Level 3 totaled \$18 million for the three months ended September 30, 2025, which relate to \$11 million of common stocks due to change in price source and \$7 million of preferred stocks transferred as a result of corporate actions. Transfers out of Level 3 totaled \$40 million for the three months ended September 30, 2025 which relate to \$38 million of other invested assets residual tranches of securitizations that were measured at fair value at the beginning of the period and measured at amortized cost at the end of the period, \$1 million of issuer credit obligations(bonds) that were measured at fair value at the beginning of the period and measured at amortized cost at the end of the period, and preferred stocks of \$1 million relate to corporate actions.

(3) Determination of fair value

The Company has an established and well-documented process for determining fair value. Security pricing is applied using a hierarchy approach whereby publicly available prices are first sought from nationally recognized third-party pricing services. For most private placement securities, the Company applies a matrix-based pricing methodology, which uses spreads derived from third-party benchmark bond indices. For private placement securities that cannot be priced through these processes, the Company uses internal models and calculations. All other securities are submitted to independent brokers for prices. The Company performs various analyses to ascertain that the prices represent fair value. Examples of procedures performed include, but are not limited to, back testing recent trades, monitoring

NEW YORK LIFE INSURANCE COMPANY
NOTES TO CONDENSED STATUTORY FINANCIAL STATEMENTS
(UNAUDITED)

trading volumes, and performing variance analysis of monthly price changes using different thresholds based on asset type. The Company also performs an annual review of all third-party pricing services. During this review, the Company obtains an understanding of the process and sources used by the pricing service to ensure that they maximize the use of observable inputs, the pricing service's frequency of updating prices, and the controls that the pricing service uses to ensure that their prices reflect market assumptions. The Company also selects a sample of securities and obtains a more detailed understanding from each pricing service regarding how they derived the price assigned to each security. Where inputs or prices do not reflect market participant assumptions, the Company will challenge these prices and apply different methodologies that will enhance the use of observable inputs and data. The Company may use non-binding broker quotes or internal valuations to support the fair value of securities that go through this formal price challenge process.

At September 30, 2025 the Company did not have any price challenges on general account and separate account securities for what it received from third party pricing services.

In addition, the Company has a pricing committee that provides oversight over the Company's prices and fair value process for securities. The committee meets quarterly and is responsible for the review and approval of the Company's valuation procedures. The committee is also responsible for the review of pricing exception reports as well as the review of significant inputs used in the valuation of assets that are valued internally.

For Level 1 investments, valuations are generally based on observable inputs that reflect quoted prices for identical assets in active markets.

The fair value for Level 2 and Level 3 valuations are generally based on a combination of the market and income approach. The market approach generally utilizes market transaction data for the same or similar instruments, while the income approach involves determining fair values from discounted cash flow methodologies.

The following represents a summary of significant valuation techniques for assets and liabilities used to determine fair value, as well as the general classification of such instruments pursuant to the valuation hierarchy.

Level 1 measurements

SVO identified bond ETF

For U.S. SAP, bonds reported as Level 1 represent investments in certain SVO approved ETF and mutual funds. Valuation of these securities is based on unadjusted quoted prices in active markets that are readily and regularly available. All other ETFs and mutual funds are classified and accounted for as common stock.

Common stocks

These securities are comprised of exchange traded U.S. and foreign common stock and mutual funds. The fair value of these securities is primarily based on unadjusted quoted prices in active markets that are readily and regularly available.

Derivatives (including separate accounts liabilities – derivatives)

These derivatives are comprised of exchange traded future contracts. The fair value of these securities is primarily based on unadjusted quoted prices in active markets that are readily and regularly available.

Separate accounts assets

These assets are comprised of cash and common stocks. Common stocks are generally traded on an exchange.

Level 2 measurements

Preferred stocks

The fair value of preferred stock is obtained from third-party pricing services. Vendors generally use an income-based valuation approach by using a discounted cash flow model or it may use a market approach to arrive at the security's fair value or a combination of the two.

Bonds

The fair value of bonds is obtained from third-party pricing services, matrix-based pricing, internal models or broker quotes. Third-party pricing services generally use an income-based valuation approach by using a discounted cash-flow model or it may also use a market approach by looking at recent trades of a specific security to determine fair value on public securities or a combination of the two. Typical inputs used by these pricing services include, but are not limited to: benchmark yields, reported trades, issuer spreads, bids, offers, benchmark securities, estimated cash flows and prepayment speeds, which the Company has determined are observable inputs.

NEW YORK LIFE INSURANCE COMPANY
NOTES TO CONDENSED STATUTORY FINANCIAL STATEMENTS
(UNAUDITED)

Private placement securities are primarily priced using a market approach such as a matrix-based pricing methodology, which uses spreads derived from third-party benchmark bond indices. Specifically, the Barclays Investment Grade Corporate Index is used for investment-grade securities and the Citi High Yield Cash Index is used for below investment-grade securities. These indices are two widely recognized, reliable and well regarded benchmarks by participants in the financial services industry, which represent the broader U.S. public bond markets. The spreads derived from each matrix are adjusted for liquidity. The liquidity premium is standardized and based on market transactions.

Certain private placement securities that cannot be priced using the matrix pricing described above, are priced by an internally developed discounted cash flow model or are priced based on internal calculations. The model uses observable inputs with a discount rate based off spreads of comparable public bond issues, adjusted for liquidity, rating and maturity. The Company assigns a credit rating for private placement securities based upon internal analysis. The liquidity premium is usually based on market transactions. These securities are classified as Level 2.

For some of the private placement securities priced through the model, the liquidity adjustments may not be based on market data, but rather, calculated internally. If the impact of the liquidity adjustment, which usually requires the most judgment, is not significant to the overall value of the security, the security is still classified as Level 2. If it is deemed to be significant, the security is classified as Level 3.

Derivatives

The fair value of derivative instruments is generally derived using valuation models that use an income approach, except for derivatives, which are either exchange-traded, or the fair value is priced using broker quotations. The selection of a particular model depends upon the contractual terms of, and specific risks inherent in the instrument, as well as the availability of pricing information in the market. The Company generally uses similar models to value similar instruments. Valuation model inputs include contractual terms, yield curves, foreign exchange rates, equity prices, credit curves, measures of volatility, and other factors. OTC derivatives that trade in liquid markets, where model inputs are observable for substantially the full term, are classified as Level 2.

Other invested assets

Other invested assets include residual tranches of securitizations where the fair value is obtained from third-party pricing services. Vendors generally use an income valuation approach which is based on a discounted cash flow calculation to arrive at the fair value.

Separate accounts assets

These are assets primarily related to investments in U.S. government and treasury securities, corporate bonds and mortgage-backed securities. These separate accounts assets are valued and assigned within the fair value hierarchy, consistent with the methodologies described herein for similar financial instruments held within the general account of the Company. This also relates to investments in limited partnerships and hedge funds that use NAV where the investment can be redeemed at NAV at the measurement date or in the near-term (generally 90 days).

Level 3 measurements

Bonds

The valuation techniques for most Level 3 bonds are generally the same as those described in Level 2. However, if the investments are less liquid or are lightly traded, there is generally less observable market data, and therefore these investments will be classified as Level 3. Circumstances where observable market data are not available may include events such as market illiquidity and credit events related to the security. In addition, certain securities are priced based upon internal valuations using significant unobservable inputs. If a security could not be priced by a third-party vendor or through internal pricing models, broker quotes are received and reviewed by each investment analyst. These inputs may not be observable. Therefore, Level 3 classification is determined to be appropriate.

If the price received from third-party pricing services does not appear to reflect market activity, the Company may challenge the price. For securities which go through this formal price challenge process, a non-binding broker quote or internal valuation is used to support the fair value instead. The Company also uses non-binding broker quotes to fair value certain bonds, when the Company is unable to obtain prices from third-party vendors.

Private placement securities where adjustments for liquidity are considered significant to the overall price are classified as Level 3.

Preferred and common stocks

These securities include equity investments with privately held entities, including a government organization, where the prices are derived from internal valuations.

Derivatives

Derivatives that are valued based upon models with any significant unobservable market inputs or inputs from less actively traded markets, or where the fair value is solely derived using broker quotations, are classified as Level 3.

NEW YORK LIFE INSURANCE COMPANY
NOTES TO CONDENSED STATUTORY FINANCIAL STATEMENTS
(UNAUDITED)

Other Invested Assets

Other invested assets include preferred units of a limited partnership and residual tranches of securitizations. The fair value of the preferred units is derived internally based on market comparable and recent transactions by the limited partnership. This valuation technique used required inputs that were both unobservable and significant and therefore classified as Level 3. The fair value of the residual tranches of securitizations is derived using an income valuation approach, which is based on a discounted cash flow calculation that may or may not use observable inputs and is classified as Level 3.

Separate accounts assets

Separate accounts assets reported as Level 3 relate to investments in common stocks and preferred stocks. These are instruments whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement.

NEW YORK LIFE INSURANCE COMPANY
NOTES TO CONDENSED STATUTORY FINANCIAL STATEMENTS
(UNAUDITED)

B. The following table presents the estimated fair value and carrying value of the Company's financial instruments at September 30, 2025. Since the SSAP 100 hierarchy only applies to items that are measured at fair value at the reporting date, the items in the tables above are subsets of the amounts reported in the following table (in millions):

	Fair Value	Carrying Amount	Level 1	Level 2	Level 3	Net Asset Value (NAV)	Not Practicable (Carrying Value)	NAV Included in Level 2
Assets:								
Issuer Credit Obligations	\$ 111,424	\$ 118,989	\$ 23	\$ 107,549	\$ 3,852	\$ —	\$ —	\$ —
Asset Backed securities	31,498	32,744	—	29,730	1,769	—	—	—
Preferred stocks	235	232	—	39	196	—	—	—
Common stocks	526	526	267	—	259	—	—	—
Mortgage loans	26,085	27,018	—	—	26,085	—	—	—
Cash, cash equivalents and short-term investments	4,184	4,184	814	3,370	—	—	—	—
Derivatives	1,758	1,455	—	1,758	—	—	—	—
Other invested assets ¹	1,419	1,376	—	470	949	—	—	—
Derivative Collateral	249	249	—	249	—	—	—	—
Investment income due and accrued	2,344	2,344	—	2,344	—	—	—	—
Separate accounts assets	10,955	11,032	596	9,150	73	1,136	—	—
Total assets	\$ 190,677	\$ 200,149	\$ 1,700	\$ 154,659	\$ 33,183	\$ 1,136	\$ —	\$ —
Liabilities:								
Deposit fund contracts:								
Funding agreements	\$ 48,635	\$ 48,906	\$ —	\$ —	\$ 48,635	\$ —	\$ —	\$ —
Annuities certain	10	10	—	—	10	—	—	—
Other deposit funds	—	1,239	—	—	—	—	—	—
Premiums paid in advance	125	—	—	125	—	—	—	—
Derivatives	711	686	—	711	—	—	—	—
Derivatives - collateral	736	736	—	736	—	—	—	—
Borrowed money	473	473	—	473	—	—	—	—
Payable to parent and affiliates	29	29	—	29	—	—	—	—
Amounts payable under securities lending	504	504	—	504	—	—	—	—
Separate accounts liabilities - derivatives	—	—	—	—	—	—	—	—
Separate accounts liabilities - derivative collateral	—	—	—	—	—	—	—	—
Separate accounts liabilities	—	—	—	—	—	—	—	—
Total liabilities	\$ 51,223	\$ 52,582	\$ —	\$ 2,578	\$ 48,645	\$ —	\$ —	\$ —

¹ Excludes investments accounted for under the equity method.

Bonds

The fair value of bonds is determined by considering one of four primary sources: (1) security pricing is applied using a hierarchy approach whereby publicly available prices are first sought from nationally recognized third-party pricing services, (2) securities are priced using a matrix-based pricing methodology, which uses spreads derived from third-party benchmark bond indices, (3) securities are priced using an internal pricing model or methodology, and (4) securities are submitted to independent brokers for prices.

The pricing service generally uses an income-based valuation approach by using a discounted cash-flow model or it may also use a market approach by looking at recent trades of a specific security to determine fair value or a combination of the two. Typical inputs used by these pricing services include, but are not limited to: benchmark yields, reported trades, issuer spreads, bids, offers, benchmark securities, estimated cash flows and prepayment speeds.

Independent pricing vendors do not supply prices for private placement bonds. These securities are primarily priced using a market approach such as a matrix-based pricing methodology, which uses spreads derived from third-party benchmark bond indices. Any private securities that cannot be priced using this methodology, are priced using an internally developed model based upon assigned comparable public issues adjusted for liquidity, maturity and rating, or are priced based on internal calculations. The Company assigns a credit rating based upon internal analysis.

NEW YORK LIFE INSURANCE COMPANY
NOTES TO CONDENSED STATUTORY FINANCIAL STATEMENTS
(UNAUDITED)

Prices from pricing services and broker quotes are validated on an ongoing basis to ensure the adequacy and reliability of the fair value measurement. The Company performs both quantitative and qualitative analysis of the prices including initial and ongoing review of third-party pricing methodologies, back testing of recent trades, and a thorough review of pricing trends and statistics.

Included in bonds is an affiliated bond from Madison Capital Funding LLC ("MCF"). The affiliated bond from MCF had a carrying value of \$3,582 million and a fair value of \$3,591 million at September 30, 2025. The fair value of this security is calculated internally and may include inputs that may not be observable. Therefore, this security is classified as Level 3.

Preferred stocks

Preferred stocks valued using prices from third-party pricing services generally use a discounted cash flow model or a market approach to arrive at the security's fair value and are classified as Level 2. Preferred stocks classified as Level 3 are valued based on internal valuations where significant inputs are deemed to be unobservable.

Common stocks

These securities are comprised of exchange traded U.S. and foreign common stock and mutual funds. The fair value of these securities is primarily based on unadjusted quoted prices in active markets that are readily and regularly available and are classified as Level 1. Common stocks that do not trade in an active market and are valued based on prices obtained from independent pricing vendors using unadjusted quoted prices in active markets for similar securities that are readily and regularly available are classified as level 2. Common stocks priced through an internal valuation where significant inputs are deemed to be unobservable, including securities issued by government organizations where fair value is fixed, are classified as Level 3.

Mortgage loans

The estimated fair value of mortgage loans is determined using an income approach, based upon the present value of the expected cash flows discounted at a market yield using an internally calculated spread. The spread is based on management's judgment and assumptions, which takes into account matters such as property type, LTV and remaining term of each loan, etc. The spread is a significant component of the pricing inputs, and therefore, these investments are classified as Level 3.

Cash, cash equivalents, short-term investments and investment income due and accrued

Cash on hand and money market mutual funds are classified as Level 1. Cash overdrafts (i.e. outstanding checks) are classified as Level 2. Due to the short-term maturities of cash equivalents, short term investments, and investment income due and accrued, carrying value approximates fair value and is classified as Level 2.

Derivatives (including separate accounts liabilities)

The fair value of derivative instruments is generally derived using valuation models that use an income approach, except for derivatives that are exchange-traded, which are valued using quoted prices in an active market. Where valuation models are used, the selection of a particular model depends upon the contractual terms of, and specific risks inherent in the instrument, as well as the availability of pricing information in the market. The Company generally uses similar models to value similar instruments. Valuation model inputs include contractual terms, yield curves, foreign exchange rates, equity prices, credit curves, measures of volatility and other factors. Exchange-traded derivatives are valued using a market approach as fair value is based on quoted prices in active market and are classified as Level 1. OTC derivatives that trade in liquid markets, where model inputs are observable for substantially the full term, are classified as Level 2. Derivatives that are valued based upon models with any significant unobservable market inputs or inputs from less actively traded markets, or where the fair value is solely derived using broker quotations, are classified as Level 3.

Derivatives Collateral (including Separate Accounts Liabilities - Collateral)

The carrying value of these instruments approximates fair value since these assets and liabilities are generally short-term in nature and are classified as Level 2.

Other invested assets

Other invested assets are principally comprised of tax credit investments, surplus notes, capital notes, single asset single borrower commercial mortgage backed securities, affiliated loans, residual tranches of securitizations and other investments with characteristics of debt. Surplus notes, capital notes and single asset single borrower commercial mortgage backed securities are valued using prices from third-party pricing services that generally use a discounted cash-flow model or a market approach to arrive at the security's fair value and are classified as Level 2. The fair value of affiliated loans and the tax credit investments is derived using an income valuation approach, which is based on a discounted cash flow calculation using a discount rate that is determined internally and therefore classified as Level 3. The fair value of the majority of the other investments with debt characteristics and the majority of the residual tranches of securitizations is derived using an income valuation approach, which is based on a discounted cash flow calculation that may or may not use observable inputs and therefore is classified as Level 3.

NEW YORK LIFE INSURANCE COMPANY
NOTES TO CONDENSED STATUTORY FINANCIAL STATEMENTS
(UNAUDITED)

Separate accounts assets (including Collateral)

Separate accounts assets reported as Level 1 in the fair value hierarchy are comprised of cash and common stocks. Common stocks are generally traded on an exchange. Separate accounts assets reported as Level 2 relate to investments in U.S. government and treasury securities, corporate bonds and mortgage-backed securities. These separate accounts assets are valued and assigned within the fair value hierarchy, consistent with the methodologies described herein for similar financial instruments held within the general account of the Company. The separate accounts also invest in limited partnerships and hedge fund investments. The fair value of such partnerships is determined by reference to the limited partnership's net asset value ("NAV"). The valuation of the hedge funds is based upon the hedge funds' latest financial statements adjusted for cash activity since that date and estimates of market valuations.

Separate accounts assets reported as Level 3 relate to investments in corporate bonds. These are instruments whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement.

Deposit fund contracts

For funding agreements backing medium term notes, fair values are based on available market prices for the notes. For other funding agreements and annuities certain liabilities, fair values are estimated using discounted cash flow calculations based on interest rates currently being offered for similar contracts with maturities consistent with those remaining for the contracts being valued. For all other deposit funds, the fair value is estimated to be equal to the account value since they can be withdrawn at anytime and without prior notice.

Premiums paid in advance

For premiums paid in advance, the carrying value of the liability approximates fair value.

Amounts payable under securities lending

Amounts due under securities lending consists of cash collateral received under securities lending agreements. Due to the short-term nature of the transactions, the carrying value approximates fair value.

- C. If it is not practicable for an entity to estimate the fair value of that financial instrument or a class of financial instruments, the following shall be disclosed:

(1) – (2) Not applicable.

- D. The following table provides additional information for investments that are measured using NAV as a practical expedient to estimate fair value, as allowed under authoritative guidance, for investments that meet specified criteria (in millions):

September 30, 2025					
Category of Investment	Investment Strategy	Fair Value Determined Using NAV	Unfunded Commitments	Redemption Frequency	Redemption Notice Period
Hedge fund	Long/short equity, futures, options, foreign exchange arbitrage	\$ 7	\$ —	Annual, Semi-Annual, Quarterly, Monthly	30-90 days (Assets subject to lock-up periods)
Hedge fund	Distressed securities, multi-strategy	1	—	Semi-Annual, Quarterly	60-90 days (Assets subject to lock-up periods)
Private equity	Leverage buyout, mezzanine financing, distressed securities	1,129	195	N/A	N/A
		<u>\$ 1,137</u>	<u>\$ 195</u>		

Note 3 - Subsequent Events

At November 12, 2025, the date the financial statements were available to be issued, there have been no events occurring subsequent to the close of the Company's books or accounts which would have a material effect on the financial condition of the Company.